Literature DB >> 9447986

Stoichiometric structure-function analysis of the prolactin receptor signaling domain by receptor chimeras.

W P Chang1, Y Ye, C V Clevenger.   

Abstract

The intracellular domain of the prolactin (PRL) receptor (PRLr) is required for PRL-induced signaling and proliferation. To identify and test the functional stoichiometry of those PRLr motifs required for transduction and growth, chimeras consisting of the extracellular domain of either the alpha or beta subunit of human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor (GM-CSFr) and the intracellular domain of the rat PRLr were synthesized. Because the high-affinity binding of GM-CSF results from the specific pairing of one alpha- and one beta-GM-CSFr, use of GM-CSFr/PRLr chimera enabled targeted dimerization of the PRLr intracellular domain. To that end, the extracellular domains of the alpha- and beta-GM-CSFr were conjugated to one of the following mutations: (i) PRLr C-terminal truncations, termed alpha278, alpha294, alpha300, alpha322, or beta322; (ii) PRLr tyrosine replacements, termed Y309F, Y382F, or Y309+382F; or, (iii) PRLr wild-type short, intermediate, or long isoforms. These chimeras were cotransfected into the cytokine-responsive Ba/F3 line, and their expression was confirmed by ligand binding and Northern and Western blot analyses. Data from these studies revealed that heterodimeric complexes of the wild type with C-terminal truncation mutants of the PRLr intracellular domain were incapable of ligand-induced signaling or proliferation. Replacement of any single tyrosine residue (Y309F or Y382F) in the dimerized PRLr complex resulted in a moderate reduction of receptor-associated Jak2 activation and proliferation. In contrast, trans replacement of these residues (i.e., alphaY309F and betaY382F) markedly reduced ligand-driven Jak2 activation and proliferation, while cis replacement of both tyrosine residues in a single intracellular domain (i.e., alphaY309+382F) produced an inactive signaling complex. Analysis of these GM-CSFr-PRLr complexes revealed equivalent levels of Jak2 in association with the mutant receptor chains, suggesting that the tyrosine residues at 309 and 382 do not contribute to Jak association, but instead to its activation. Heterodimeric pairings of the intracellular domains from the known PRLr receptor isoforms (short-intermediate, short-long, and intermediate-long) also yielded inactive receptor complexes. These data demonstrate that the tyrosine residues at 309 and 382, as well as additional residues within the C terminus of the dimerized PRLr complex, contribute to PRL-driven signaling and proliferation. Furthermore, these findings indicate a functional requirement for the pairing of Y309 and Y382 in trans within the dimerized receptor complex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9447986      PMCID: PMC108801          DOI: 10.1128/MCB.18.2.896

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  65 in total

1.  Role of Bag-1 in the survival and proliferation of the cytokine-dependent lymphocyte lines, Ba/F3 and Nb2.

Authors:  C V Clevenger; K Thickman; W Ngo; W P Chang; S Takayama; J C Reed
Journal:  Mol Endocrinol       Date:  1997-05

2.  Modulation of growth factor receptor function by isoform heterodimerization.

Authors:  W P Chang; C V Clevenger
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Inhibition of lymphocyte proliferation by antibodies to prolactin.

Authors:  D P Hartmann; J W Holaday; E W Bernton
Journal:  FASEB J       Date:  1989-08       Impact factor: 5.191

4.  Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's.

Authors:  M Hatakeyama; M Tsudo; S Minamoto; T Kono; T Doi; T Miyata; M Miyasaka; T Taniguchi
Journal:  Science       Date:  1989-05-05       Impact factor: 47.728

5.  Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor gene family.

Authors:  J M Boutin; C Jolicoeur; H Okamura; J Gagnon; M Edery; M Shirota; D Banville; I Dusanter-Fourt; J Djiane; P A Kelly
Journal:  Cell       Date:  1988-04-08       Impact factor: 41.582

Review 6.  Prolactin as a mitogen in mammary cells.

Authors:  R Das; B K Vonderhaar
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

Review 7.  Prolactin as an autocrine/paracrine factor in breast tissue.

Authors:  C V Clevenger; T L Plank
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-01       Impact factor: 2.673

8.  Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells.

Authors:  J M Boutin; M Edery; M Shirota; C Jolicoeur; L Lesueur; S Ali; D Gould; J Djiane; P A Kelly
Journal:  Mol Endocrinol       Date:  1989-09

9.  Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.

Authors:  R Palacios; M Steinmetz
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

10.  Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice.

Authors:  E W Bernton; M S Meltzer; J W Holaday
Journal:  Science       Date:  1988-01-22       Impact factor: 47.728

View more
  10 in total

Review 1.  The ovarian gonadotropin receptors in health and disease.

Authors:  Paul A Fowler; Ilpo T Huhtaniemi
Journal:  Rev Endocr Metab Disord       Date:  2002-01       Impact factor: 6.514

2.  Regulation of transcription factors and repression of Sp1 by prolactin signaling through the short isoform of its cognate receptor.

Authors:  Y Sangeeta Devi; Aurora Shehu; Carlos Stocco; Julia Halperin; Jamie Le; Anita M Seibold; Michal Lahav; Nadine Binart; Geula Gibori
Journal:  Endocrinology       Date:  2009-04-02       Impact factor: 4.736

3.  Inhibition of MAPK by prolactin signaling through the short form of its receptor in the ovary and decidua: involvement of a novel phosphatase.

Authors:  Y Sangeeta Devi; Anita M Seibold; Aurora Shehu; Evelyn Maizels; Julia Halperin; Jamie Le; Nadine Binart; Lei Bao; Geula Gibori
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

4.  Generation of mice expressing only the long form of the prolactin receptor reveals that both isoforms of the receptor are required for normal ovarian function.

Authors:  Jamie A Le; Heather M Wilson; Aurora Shehu; Jifang Mao; Y Sangeeta Devi; Julia Halperin; Tetley Aguilar; Anita Seibold; Evelyn Maizels; Geula Gibori
Journal:  Biol Reprod       Date:  2012-03-22       Impact factor: 4.285

5.  A novel and functional interaction between cyclophilin A and prolactin receptor.

Authors:  Farhat Syed; Michael A Rycyzyn; Liz Westgate; Charles V Clevenger
Journal:  Endocrine       Date:  2003 Feb-Mar       Impact factor: 3.633

Review 6.  Breast Cancer and Prolactin - New Mechanisms and Models.

Authors:  Charles V Clevenger; Hallgeir Rui
Journal:  Endocrinology       Date:  2022-10-01       Impact factor: 5.051

Review 7.  Regulation of prolactin receptor levels and activity in breast cancer.

Authors:  G Swaminathan; B Varghese; S Y Fuchs
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

Review 8.  Molecular mechanisms of prolactin and its receptor.

Authors:  Charles L Brooks
Journal:  Endocr Rev       Date:  2012-05-10       Impact factor: 19.871

9.  The human intermediate prolactin receptor is a mammary proto-oncogene.

Authors:  Jacqueline M Grible; Patricija Zot; Amy L Olex; Shannon E Hedrick; J Chuck Harrell; Alicia E Woock; Michael O Idowu; Charles V Clevenger
Journal:  NPJ Breast Cancer       Date:  2021-03-26

10.  Convergent Evolution of Slick Coat in Cattle through Truncation Mutations in the Prolactin Receptor.

Authors:  Laercio R Porto-Neto; Derek M Bickhart; Antonio J Landaeta-Hernandez; Yuri T Utsunomiya; Melvin Pagan; Esbal Jimenez; Peter J Hansen; Serdal Dikmen; Steven G Schroeder; Eui-Soo Kim; Jiajie Sun; Edward Crespo; Norman Amati; John B Cole; Daniel J Null; Jose F Garcia; Antonio Reverter; William Barendse; Tad S Sonstegard
Journal:  Front Genet       Date:  2018-02-23       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.